Chemical formula: C₂₄H₃₁NO Molecular mass: 349.509 g/mol PubChem compound: 132971
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L02BX03 | Abiraterone | L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZYTIGA Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ZYTIGA Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Abiraterone is an active ingredient of these brands:
Australia (AU)
Brazil (BR)Canada (CA)
Cyprus (CY)
Ecuador (EC)Estonia (EE)
Ireland (IE)
Israel (IL)
Italy (IT)
Japan (JP)
Lithuania (LT)Mexico (MX)
Netherlands (NL)
Nigeria (NG)
Poland (PL)Spain (ES)
Tunisia (TN)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
